EDIT - エディタス・メディシン (Editas Medicine Inc.) エディタス・メディシン

 EDITのチャート


 EDITの企業情報

symbol EDIT
会社名 Editas Medicine Inc (エディタス・メディシン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エディタス・メディシン(Editas Medicine Inc.)はゲノム編集会社である。同社は、疾患の原因となる遺伝子を編集することによって、遺伝子疾患を有する患者を治療する。同社はゲノム編集技術分野での開発と商品化を通じて事業を展開する。同社はクラスター化され、規則的に間隔を置いて配置された短いパリンドローム反復(CRISPR)技術に基づくゲノム編集プラットフォームを開発している。CRISPRは、CRISPR関連タンパク質9(Cas9)またはPrevotellaおよびFrancisella 1(Cpf1)由来のCRISPRのいずれかを含む酵素からなるタンパク質 - リボ核酸(RNA)複合体を使用し、特定のデオキシリボ核酸(DNA)配列を認識するように設計されたガイドRNA分子に結合する。同社のプラットフォームは、ヌクレアーゼエンジニアリング、デリバリー、コントロールと特異性、指示編集の4つのコンポーネントから構成される。同社のプログラムには、眼疾患、免疫腫瘍学のための人工T細胞療法、および追加の研究プログラムが含まれる。同社はLeber先天性アメロシスタイプ10(LCA10)のゲノム編集治療薬を開発している。   エディタス・メディシンは米国のライフサイエンス企業。病原性遺伝子ゲノム編集により、遺伝子関連疾患を治療する。ゲノム編集プラットフォ―ム「CRISPR/Cas9」を商標登録し、特定のDNAを認識し削除した後ゲノム配列を編集する技術を開発。同社プラットフォ―ムにはヌクレア―ゼ、送達システム、ゲノム編集などを含む。本社はマサチュ―セッツ州ケンブリッジ。  
本社所在地 11 Hurley Street Cambridge MA 02141 USA
代表者氏名 James C. Mullen ジェームスC.ミューレン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-401-9000
設立年月日 41518
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 112人
url www.editasmedicine.com
nasdaq_url https://www.nasdaq.com/symbol/edit
adr_tso
EBITDA EBITDA(百万ドル) -131.47100
終値(lastsale) 27.88
時価総額(marketcap) 1329196954.72
時価総額 時価総額(百万ドル) 1323.476
売上高 売上高(百万ドル) 21.24800
企業価値(EV) 企業価値(EV)(百万ドル) 112.34
当期純利益 当期純利益(百万ドル) -132.45000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Editas Medicine Inc revenues increased from $3.8M to $11.3M. Net loss increased 21% to $69.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 56% to $46.1M (expense) General and administrative - Balancing increase of 14% to $22.9M (expense).

 EDITのテクニカル分析


 EDITのニュース

   Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc  2021/03/23 11:13:10 OpenPR
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
   CRISPR and CAS Gene Market – Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript  2021/03/02 07:34:47 OpenPR
CRISPR and CAS Gene Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results  2021/02/26 16:09:01 Transcript Daily
Editas Medicine (NASDAQ:EDIT) posted its quarterly earnings data on Thursday. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.19), MarketWatch Earnings reports. The company had revenue of $11.42 million during the quarter, compared to analyst estimates of $5.64 million. Editas Medicine had a negative return on […]
   Editas Medicine Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2021/02/24 15:28:00 Stock Market Daily
Editas Medicine announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Better Buy: CRISPR Therapeutics vs. Editas Medicine  2021/02/05 11:10:00 The Motley Fool
Which of these two hot gene therapy stocks is the better buy?
   Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc  2021/03/23 11:13:10 OpenPR
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
   CRISPR and CAS Gene Market – Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript  2021/03/02 07:34:47 OpenPR
CRISPR and CAS Gene Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results  2021/02/26 16:09:01 Transcript Daily
Editas Medicine (NASDAQ:EDIT) posted its quarterly earnings data on Thursday. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.19), MarketWatch Earnings reports. The company had revenue of $11.42 million during the quarter, compared to analyst estimates of $5.64 million. Editas Medicine had a negative return on […]
   Editas Medicine Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2021/02/24 15:28:00 Stock Market Daily
Editas Medicine announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Better Buy: CRISPR Therapeutics vs. Editas Medicine  2021/02/05 11:10:00 The Motley Fool
Which of these two hot gene therapy stocks is the better buy?
   Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson Sells 1,568 Shares of Stock  2021/01/14 11:44:57 Watchlist News
Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson sold 1,568 shares of Editas Medicine stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average price of $78.27, for a total transaction of $122,727.36. Following the sale, the chief financial officer now directly owns 18,432 shares of the company’s stock, […]
   Editas Medicine's science head Albright leaves for new job just as biotech gets trial clearance for sickle cell therapy  2021/01/11 16:11:12 Endpoints News
Editas Medicine has received the FDA’s blessing to enter the clinic with its first ex vivo cell therapy — but it will do so without CSO Charles Albright, who is leaving his post for the same gig at an early-stage company. The FDA clearance was announced minutes after Editas shared
   Covid-19 Impact On CRISPR and CAS Gene Market Swot Analysis by Key Players: Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific  2021/01/11 13:36:57 OpenPR
COHERENT MARKET INSIGHTS has added a new report titled Global CRISPR and CAS Gene Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. This CRISPR and CAS Gene Market
   Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial - Stocks News Feed  2021/01/11 11:02:00 Stocks News Feed
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the Company can begin dosing patients. The Company is required to develop and… Read More »Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial
   Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells, Can Industry Giants take advantage of this Advancement? | Key PLayers: Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences  2021/01/07 06:47:59 OpenPR
Clusters of regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) is an innovative genome editing tool that has recently changed the field of human genetic engineering. CRISPR/Cas9 can regulate gene expression in plants, humans, and animals based on

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エディタス・メディシン EDIT Editas Medicine Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)